As depletion of OSM and IL-6 from conditioned medium of Tu-Gr1+CD11b+ is sufficient to suppress in vivo metastasis of in vitro–cocultured tumor cells, OMS/IL-6 inhibition may be considered as an alternative adjuvant strategy to prevent progression to metastases, with potential clinical benefit for patients. This evidence concerns the gene ITGAM and neoplasm.